Also Clin0 autoimmune disease; DR-0201 Clin0 B-cell malignancies; DR-02 3 efforts RD/Clin0 solid tumors, RD light chain amyloidosis
Dren Bio is using protein engineering technologies to develop therapeutic antibodies for cancer and autoimmune diseases. Current research suggests that many diseases can be treated if the relevant elements of the immune system can be activated. Dren’s approach is to selectively engage and deplete pathologic cells, protein aggregates or other disease-causing agents, by designing engineered antibodies. Their pipeline currently has two distinct programs. Dren’s lead program, DR-01, falls under their antibody-dependent cellular cytotoxicity program for antibody mediated killing of target cells. Their second program, Targeted Myeloid Engager and Phagocytosis Platform, uses Dren’s proprietary bispecific antibodies to engage both immune and cancer cells to support durable anti-tumor immune responses.